NCCN 2018-2019 Oncology Case Manager and Medical Director Program: Update on Management of Acute Lymphoblastic Leukemia

January 16, 2019

Despite the high rate of complete remission for patients with ALL, a majority of patients will develop relapsed or refractory disease. Recent advances expanding available therapeutic options could change the standard of care for these patients. In addition to recognizing the clinical benefits of these novel agents, awareness of the fundamental differences associated with treatment, including identification of unique adverse events and implementation of strategies to mitigate these events, should be addressed.

Target Audience

This program is designed to meet the educational needs of case managers, nurses in other roles (e.g., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.

Learning Objectives

Following this activity, participants should be able to:

  • Review currently approved therapies for ALL treatment.
  • Identify novel agents being investigated for ALL management.
  • Summarize risks associated with ALL treatment and management strategies.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Celgene Corporation
  • Ethicon
  • Novartis Pharmaceuticals
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Course summary
Available credit: 
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 CCM clock hours
  • 1.25 Participation
Course opens: 
11/08/2018
Course expires: 
03/10/2019
Event starts: 
01/16/2019 - 11:00am
Event ends: 
01/16/2019 - 12:15pm
Cost:
$0.00

Bijal Shah, MD
Moffitt Cancer Center

Danielle Nassello, APRN-BC
Moffitt Cancer Center

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Danielle Nasello, APRN-BC

The faculty listed below disclose the following relevant financial relationships:
Bijal Shah, MD 
Amgen Inc.: Product/Speakers Bureau 
Celgene Corporation: Scientific Advisor 
Incyte Corporation: Grant/Research Support 
Jazz Pharmaceuticals Inc.: Grant/Research Support 
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pharmacyclics: Consulting Fees, Honoraria

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (employed by NCCN until 8/10/2018); Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP (employed by NCCN until 12/3/2018)
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

Katherine Pierce (employed by NCCN until 11/16/2018)
Boston Scientific Corporation: Equity Interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Ndiya Ogba, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: 0836-0000-19-001-L01-P

Physician Assistants 
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hours of Category 1 credit for completing this activity.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.25 CE contact hours. Activity Code: I00035067; Approval #: 180004753

Available Credit

  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 CCM clock hours
  • 1.25 Participation

Accreditation Period

Course opens: 
11/08/2018
Course expires: 
03/10/2019

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Wednesday, January 16, 2019, from 11:00 AM - 12:15 PM Eastern Standard Time (EST) (UTC -5).

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing